211 related articles for article (PubMed ID: 18715787)
1. Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.
Nakashima H; Uto Y; Nakata E; Nagasawa H; Ikkyu K; Hiraoka N; Nakashima K; Sasaki Y; Sugimoto H; Shiro Y; Hashimoto T; Okamoto Y; Asakawa Y; Hori H
Bioorg Med Chem; 2008 Sep; 16(18):8661-9. PubMed ID: 18715787
[TBL] [Abstract][Full Text] [Related]
2. Design of novel hypoxia-targeting IDO hybrid inhibitors conjugated with an unsubstituted L-TRP as an IDO affinity moiety.
Nakashima H; Ikkyu K; Nakashima K; Sano K; Uto Y; Nakata E; Nagasawa H; Sugimoto H; Shiro Y; Nakagawa Y; Hori H
Adv Exp Med Biol; 2010; 662():415-21. PubMed ID: 20204824
[TBL] [Abstract][Full Text] [Related]
3. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
Hay MP; Pruijn FB; Gamage SA; Liyanage HD; Kovacs MS; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2004 Jan; 47(2):475-88. PubMed ID: 14711317
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
Hay MP; Gamage SA; Kovacs MS; Pruijn FB; Anderson RF; Patterson AV; Wilson WR; Brown JM; Denny WA
J Med Chem; 2003 Jan; 46(1):169-82. PubMed ID: 12502371
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
Xia Q; Zhang L; Zhang J; Sheng R; Yang B; He Q; Hu Y
Eur J Med Chem; 2011 Mar; 46(3):919-26. PubMed ID: 21281992
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, structure and hypoxic cytotoxicity of 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.
Jiang F; Weng Q; Sheng R; Xia Q; He Q; Yang B; Hu Y
Arch Pharm (Weinheim); 2007 May; 340(5):258-63. PubMed ID: 17464965
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.
Hay MP; Pchalek K; Pruijn FB; Hicks KO; Siim BG; Anderson RF; Shinde SS; Phillips V; Denny WA; Wilson WR
J Med Chem; 2007 Dec; 50(26):6654-64. PubMed ID: 18052317
[TBL] [Abstract][Full Text] [Related]
9. Putative electron-affinic radiosensitizers and markers of hypoxic tissue: Synthesis and preliminary in vitro biological characterization of C3-amino-substituted benzotriazine dioxides (BTDOs).
Elsaidi HR; Yang XH; Ahmadi F; Weinfeld M; Wiebe LI; Kumar P
Eur J Med Chem; 2019 Mar; 165():216-224. PubMed ID: 30684798
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.
Miyazaki T; Moritake K; Yamada K; Hara N; Osago H; Shibata T; Akiyama Y; Tsuchiya M
J Neurosurg; 2009 Aug; 111(2):230-7. PubMed ID: 19199463
[TBL] [Abstract][Full Text] [Related]
11. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.
Metz R; Duhadaway JB; Kamasani U; Laury-Kleintop L; Muller AJ; Prendergast GC
Cancer Res; 2007 Aug; 67(15):7082-7. PubMed ID: 17671174
[TBL] [Abstract][Full Text] [Related]
12. Medicinal electronomics bricolage design of hypoxia-targeting antineoplastic drugs and invention of boron tracedrugs as innovative future-architectural drugs.
Hori H; Uto Y; Nakata E
Anticancer Res; 2010 Sep; 30(9):3233-42. PubMed ID: 20944092
[TBL] [Abstract][Full Text] [Related]
13. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
14. Discovery of IDO1 and DNA dual targeting antitumor agents.
Fang K; Wu S; Dong G; Wu Y; Chen S; Liu J; Wang W; Sheng C
Org Biomol Chem; 2017 Dec; 15(47):9992-9995. PubMed ID: 29177308
[TBL] [Abstract][Full Text] [Related]
15. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
Löb S; Königsrainer A; Zieker D; Brücher BL; Rammensee HG; Opelz G; Terness P
Cancer Immunol Immunother; 2009 Jan; 58(1):153-7. PubMed ID: 18418598
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway.
Nagasawa H; Mikamo N; Nakajima Y; Matsumoto H; Uto Y; Hori H
Anticancer Res; 2003; 23(6a):4427-34. PubMed ID: 14666730
[TBL] [Abstract][Full Text] [Related]
17. Research progress of indoleamine 2,3-dioxygenase inhibitors.
Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
[TBL] [Abstract][Full Text] [Related]
18. Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.
Yang S; Li X; Hu F; Li Y; Yang Y; Yan J; Kuang C; Yang Q
J Med Chem; 2013 Nov; 56(21):8321-31. PubMed ID: 24099220
[TBL] [Abstract][Full Text] [Related]
19. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
Yang HJ; Yen MC; Lin CC; Lin CM; Chen YL; Weng TY; Huang TT; Wu CL; Lai MD
Exp Biol Med (Maywood); 2010 Jul; 235(7):869-76. PubMed ID: 20558841
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives.
Nagasawa H; Yamashita M; Mikamo N; Shimamura M; Oka S; Uto Y; Hori H
Comp Biochem Physiol A Mol Integr Physiol; 2002 May; 132(1):33-40. PubMed ID: 12062188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
